Donepezi, an acetylcholinesterase inhibitor, exhibits beneficial effects in Alzheimer’s disease through activation of the PI3K/Akt/HIF-1α/VEGF pathway (Kakinuma et al., 2010). This evidence concerns the gene HIF1A and early-onset autosomal dominant Alzheimer disease.